Though there are a number of direct players in the industry, some of the most surprising growth can be seen in emerging industry players. One such name is Scotts Miracle-Gro.
Tag Archives: Stock
The first cannabis stock ETF of its kind, the Horizons Marijuana Life Sciences Index ETF allows investors to own more than a dozen pot stocks through a single investment fund. Today, however, is a different story.
In late May, MedReleaf priced its public offering at just over $7 per share. The marijuana stock IPO raised a whopping $75 million. Unfortunately, things didn’t work out as planned for pot investors or MedReleaf.
Aurora Cannabis Inc. has been a favourite marijuana stock for some time. Should you be watching closely for an opportunity to buy the dip?
There are a handful of legitimate cultivators at this time, and an intriguing small-cap company is Aphria Inc. This marijuana stock is currently trading around $4.00, with a market cap of $579.3 million.
On May 19, 2017, Beleave Inc. (CNX:BE) announced that its subsidiary, First Access Medical Inc., had been awarded a cultivation license from Health Canada, prompting the Canadian cannabis stock to rise 7.62% on Friday.
Canopy Growth Corp.’s now down approximately 36% since my warning that the stock could be heading for a correction that would be triggered by the banned pesticides scandal.
The MMJ Phytotech Ltd share price has been a big mover in morning trade following the release of a positive announcement.
GREENWOOD VILLAGE, Colo., May 4, 2017 /Weed Wire/ — Leafbuyer Technologies, Inc. (OTC: LBUY) announced today the effectiveness of the 9.25 for 1 forward split of its common stock is upon the open of trading May 5th, 2017 and the stock will begin trading on a split-adjusted basis.
With two marijuana stocks already sporting market caps over $1 billion, one of these four pot stocks is likely to be next.
This past week brought a first for the investment world — a medical marijuana electronic-traded fund (ETF) made its debut.
MyDx (OTCQB:MYDX) stock chart technical analysis for March 31, 2017.
MyDx (OTCQB:MYDX) Stock Chart Technical Analysis for March 24, 2017.
Publicly-traded marijuana companies had a rough week but got a bounce Thursday following news of raids at the Cannabis Culture dispensary chain owned by Marc and Jodie Emery.
Insys Therapeutics announced a compassionate-use program for its cannabis-based epilepsy drug, igniting optimism that the company is continuing to develop marijuana medicine.
SAN DIEGO, Calif., March 3, 2017/Weed Wire/ — Mentor Capital, Inc. (OTCQB: MNTR) announced it has taken a $1.0 million position in the stock of GW Pharmaceuticals, Plc (NASDAQ: GWPH), a United Kingdom based group developing a portfolio of cannabinoid prescription medicines.
Bets on marijuana companies helped an Australian manager soar 145 percent last year to become the world’s best-performing hedge fund.
Investors are becoming more and more impressed with the job CEO Terry Booth and his team are doing at Aurora Cannabis Inc. After posting strong Q2 results and closing a C$75 million financing, there’s a lot to like with company.
In the last trading session, the stock price of Medical Marijuana Inc (OTCMKTS:MJNA) declined more than 8% to close the day at $0.112. The decline came at a share volume of 24.74 million compared to average share volume of 17.32 million.
Shares of Canadian and U.S. marijuana producers fell Friday after the Trump administration suggested a crackdown on recreational marijuana may be in the works.
Investors in cannabis companies had an eventful 2016 with the approval of recreational marijuana usage in the states of California, Massachusetts, Maine, and Nevada providing a boost to all sorts of marijuana stocks. Of particular note, shares of Corbus Pharmaceuticals (NASDAQ: CRBP) posted a whopping 600% gain in 2016 following positive phase 2 data.
It certainly has been a great day for pot stocks on the ASX. This morning Federal Health Minister Greg Hunt announced that the government would allow medical marijuana companies to distribute cannabis oils and medications in Australia within the next couple of months.
BOULDER, Colo., Feb. 21, 2017 /Weed Wire/ — Surna Inc. (OTCQB: SRNA) converted $2.76 million of its 10% convertible promissory notes, consisting of approximately $2.28 million in principal and $480,000 of accrued interest, into approximately 18 million shares of newly issued common stock and cash payments of less than $200,000.
Canopy Growth Corp. has garnered the most attention and established itself as the market leader; however, there is another company in the Canadian marijuana industry that could emerge as a potential winner.
Canopy Growth’s recently acquired Mettrum Ltd. stated that it wrote off $800,000 of costs owing to a series of recalls over the use of a banned pesticides. The staff at Mettrum feared detection from authorities, so they hid the pesticides in the office’s ceiling tiles.
Since seeing all the buzz and craze these companies are causing in the marketplace, we’ve been hot on the trail of companies tied to the cannabis sector. The budding marijuana industry has spawned several high flying stocks lately, like Mentor Capital Inc.
Over the next five years, the U.S. marijuana market could be worth tens of billions of dollars, and according to GreenWave Advisors, LLC, these five states could move the needle most for marijuana companies. Learn just how big the marijuana market may be in California, Washington, Pennsylvania, Colorado, and Michigan in 2021.
Investors are incredibly excited about Canopy Growth Corporation. But we’re now looking at a situation where the stock has increased quite aggressively thanks mostly to the belief that the future is bright. And there are still many investors sitting on the sidelines wondering if they should consider this company.
Canopy Growth Corporation’s generating eye-popping returns for investors. However, there are risks ahead that could rein in some investor optimism.
On the face of it, 2017 may be the year to jump into the marijuana market to get a piece of what looks to be promising growth over the next few years.
Cannabis Science Inc (OTC:CBIS) — Stock Chart Technical Analysis for Jan. 23, 2017.
The market for marijuana is exploding as Americans overwhelmingly embrace legalization. Analysts are projecting tens of billions of dollars in future marijuana sales, making this an intriguing market for investors.
DEVON, Pa., Jan. 19, 2017 /Weed Wire/ — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced the pricing of an underwritten public offering of 2.8 million shares of its common stock at a price of $18.00 per share, with expected gross proceeds to Zynerba of $50.4 million.
Jon Cunningham, VP of RedChip, interviews Corey Hollister, co-founder and co-chairman of American Cannabis Co. (OTCQB: AMMJ).
Real estate is the next big catalyst for marijuana stocks in 2017, as more voters demand legalized recreational and medical cannabis in their states.
Canopy Growth Corp. (TSX:CGC) has been on a wild ride in recent months, and investors who think the name has long-term potential are trying to decided when they should buy.
MassRoots Inc(OTCMKTS:MSRT) describes itself as one of the largest technology platforms for the regulated cannabis industry. MSRT is at the right place at the right time as the pot sector has been seeing huge growth in recent months as medical MJ products in the U.S. alone are projected to generate up to $35 Billion by 2020.
Sales in the legal marijuana industry are skyrocketing, which is why Money Morning created a list of the top marijuana stocks to watch in 2017. But because marijuana is still illegal under federal law, and many of the marijuana stocks on the market are so volatile, this isn’t a list of recommendations. Rather, it’s a list of marijuana stocks they are watching closely in 2017.
Further details of recall revealed that there has been a detection of an unwanted pesticide, which is not registered for use on marijuana, under the Pest Control Products Act.
Most myths have at least a little bit of truth interspersed with a lot that is false. That’s the case with these three myths about marijuana stocks that some might mistakenly believe.
Here are three stocks that have doubled investors’ money in 2016, and a look into whether or not they can continue to rally in 2017.
In the last few months, the medical marijuana growers have dominated the trading activity on the TSX Venture in terms of dollar volume almost exclusively, belying a persistent interest from investors in Canada and the United States.
While many investors were drawn in by the myth that millions would be made by investing in the companies that purportedly planned to cultivate and sell medical and leisure based marijuana, they should have been focused on investing in companies that are intent on utilizing the plant’s cannabinoid properties, which are consistently demonstrating extraordinary benefit in treating a host of medical conditions.
MassRoots Inc is a penny play in the cannabis space on the technology side that has been performing extremely well of late on several key catalysts.
DENVER, Dec. 15, 2016 /Weed Wire/ — MassRoots, Inc. (OTCQB:MSRT), one of the leading technology platforms for the cannabis industry, is pleased to report it has entered into a definitive agreement to acquire DDDigtal Inc. d.b.a. “Whaxy” & Cannabuild for $100,000 cash and 2,926,830 million shares of MassRoots’ common stock.
The fed’s report was largely positive for the recreational marijuana industry when it was released Tuesday. Aurora Cannabis stock was one of the biggest pot stock beneficiaries of the announcement, but has since had a regression in share price.
Scientists, regulators and millions suffering from pain are trying to get their hands on cannabis — but not the kind you smoke, eat or grow in an alley.
For now, CannaRoyalty is also the only option for Canadian investors to gain exposure to the U.S. recreational marijuana market.
Is Canopy Growth about to become a mega marijuana stock company?
Creso Pharma shares jumped when the medical cannabis company debuted on the ASX. The shares are up by a quarter since listing on Thursday at 25 cents.